Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200380486> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4200380486 endingPage "vi155" @default.
- W4200380486 startingPage "vi155" @default.
- W4200380486 abstract "Abstract BACKGROUND Uncontrolled seizures on antiepileptic drug (AED) monotherapy are common in glioma patients and about a third of patients need an add-on AED. The aim of this study was to determine whether levetiracetam combined with valproic acid (LEV+VPA), a commonly prescribed duotherapy, was more effective than other duotherapy combinations, which included either LEV or VPA, in glioma patients. METHODS In this multicenter observational cohort study, data of patients with a diffuse grade 2-4 glioma and having uncontrolled seizures on their first-line monotherapy LEV or VPA, was retrospectively analyzed. Primary outcome was treatment failure (i.e. replacement by or addition of a new AED, or withdrawal of an AED) for any reason. Secondary outcomes included: 1) treatment failure due to uncontrolled seizures; and 2) treatment failure due to adverse effects. Time to treatment failure was estimated with multivariable Cox proportional hazard models, from moment of AED duotherapy treatment initiation. The maximum duration of follow-up was 36 months. RESULTS A total of 355 patients received AED duotherapy after they showed treatment failure due to uncontrolled seizures on monotherapy. LEV+VPA was prescribed in 66% (236/355) and other AED duotherapy combinations including LEV or VPA in 34% (119/355) of patients. Patients using other duotherapy versus LEV+VPA had higher risk of treatment failure for any reason (cause-specific hazard ratio [csHR]=1.50 [95%CI=1.07-2.12], p=0.020), due to uncontrolled seizures (csHR=1.73 [95%CI=1.10-2.73], p=0.018), but not due to adverse effects (csHR=0.88 [95%CI=0.47-1.67]), p=0.703). CONCLUSIONS This observational cohort study showed that LEV+VPA has better efficacy than other AED combinations with either LEV or VPA, but toxicity was similar in the two groups." @default.
- W4200380486 created "2021-12-31" @default.
- W4200380486 creator A5004901028 @default.
- W4200380486 creator A5006474472 @default.
- W4200380486 creator A5027431274 @default.
- W4200380486 creator A5037395192 @default.
- W4200380486 creator A5056837393 @default.
- W4200380486 creator A5058131100 @default.
- W4200380486 creator A5085953690 @default.
- W4200380486 creator A5086283695 @default.
- W4200380486 date "2021-11-02" @default.
- W4200380486 modified "2023-10-16" @default.
- W4200380486 title "NCOG-15. THE EFFECTIVENESS OF ANTIEPILEPTIC DRUG DUOTHERAPIES IN GLIOMA PATIENTS: A MULTICENTER OBSERVATIONAL COHORT STUDY" @default.
- W4200380486 doi "https://doi.org/10.1093/neuonc/noab196.606" @default.
- W4200380486 hasPublicationYear "2021" @default.
- W4200380486 type Work @default.
- W4200380486 citedByCount "0" @default.
- W4200380486 crossrefType "journal-article" @default.
- W4200380486 hasAuthorship W4200380486A5004901028 @default.
- W4200380486 hasAuthorship W4200380486A5006474472 @default.
- W4200380486 hasAuthorship W4200380486A5027431274 @default.
- W4200380486 hasAuthorship W4200380486A5037395192 @default.
- W4200380486 hasAuthorship W4200380486A5056837393 @default.
- W4200380486 hasAuthorship W4200380486A5058131100 @default.
- W4200380486 hasAuthorship W4200380486A5085953690 @default.
- W4200380486 hasAuthorship W4200380486A5086283695 @default.
- W4200380486 hasBestOaLocation W42003804861 @default.
- W4200380486 hasConcept C118552586 @default.
- W4200380486 hasConcept C126322002 @default.
- W4200380486 hasConcept C167135981 @default.
- W4200380486 hasConcept C187212893 @default.
- W4200380486 hasConcept C197934379 @default.
- W4200380486 hasConcept C207103383 @default.
- W4200380486 hasConcept C23131810 @default.
- W4200380486 hasConcept C2777172819 @default.
- W4200380486 hasConcept C2777332695 @default.
- W4200380486 hasConcept C2778186239 @default.
- W4200380486 hasConcept C2778227246 @default.
- W4200380486 hasConcept C44249647 @default.
- W4200380486 hasConcept C502942594 @default.
- W4200380486 hasConcept C71924100 @default.
- W4200380486 hasConcept C72563966 @default.
- W4200380486 hasConceptScore W4200380486C118552586 @default.
- W4200380486 hasConceptScore W4200380486C126322002 @default.
- W4200380486 hasConceptScore W4200380486C167135981 @default.
- W4200380486 hasConceptScore W4200380486C187212893 @default.
- W4200380486 hasConceptScore W4200380486C197934379 @default.
- W4200380486 hasConceptScore W4200380486C207103383 @default.
- W4200380486 hasConceptScore W4200380486C23131810 @default.
- W4200380486 hasConceptScore W4200380486C2777172819 @default.
- W4200380486 hasConceptScore W4200380486C2777332695 @default.
- W4200380486 hasConceptScore W4200380486C2778186239 @default.
- W4200380486 hasConceptScore W4200380486C2778227246 @default.
- W4200380486 hasConceptScore W4200380486C44249647 @default.
- W4200380486 hasConceptScore W4200380486C502942594 @default.
- W4200380486 hasConceptScore W4200380486C71924100 @default.
- W4200380486 hasConceptScore W4200380486C72563966 @default.
- W4200380486 hasIssue "Supplement_6" @default.
- W4200380486 hasLocation W42003804861 @default.
- W4200380486 hasLocation W42003804862 @default.
- W4200380486 hasOpenAccess W4200380486 @default.
- W4200380486 hasPrimaryLocation W42003804861 @default.
- W4200380486 hasRelatedWork W1966719757 @default.
- W4200380486 hasRelatedWork W1967940919 @default.
- W4200380486 hasRelatedWork W2038751567 @default.
- W4200380486 hasRelatedWork W2565914894 @default.
- W4200380486 hasRelatedWork W2792584059 @default.
- W4200380486 hasRelatedWork W3008396421 @default.
- W4200380486 hasRelatedWork W3013372623 @default.
- W4200380486 hasRelatedWork W3016970870 @default.
- W4200380486 hasRelatedWork W3215324468 @default.
- W4200380486 hasRelatedWork W8168635 @default.
- W4200380486 hasVolume "23" @default.
- W4200380486 isParatext "false" @default.
- W4200380486 isRetracted "false" @default.
- W4200380486 workType "article" @default.